Loading…
Based on limited metadata, the FDA issued a Warning Letter to Reine Lifescience on May 9, 2018, regarding an unspecified product type classified as "Other." Without access to the full warning letter text or specific subject line details, the exact nature of the violations cannot be determined from the available information. The issuing office is not specified in the metadata provided, limiting visibility into the specific regulatory division overseeing this enforcement action. Additional documentation would be needed to identify the particular compliance issues that prompted this warning.